Relay Therapeutics amended its certificate of incorporation to increase total authorized capital stock from an unstated prior amount to 460 million shares, comprising 450 million common shares and 10 million preferred shares. The amendment provides the company flexibility for future financing, equity compensation, or strategic transactions.